Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ultragenyx Pharmaceu (NQ: RARE ) 43.89 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 43.89 Bid (Size) 43.88 (1) Ask (Size) 46.97 (1) Prev. Close 43.89 Today's Range 43.89 - 43.89 52wk Range 31.52 - 54.56 Shares Outstanding 70,814,462 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program July 17, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 20, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Performance YTD -8.89% -8.89% 1 Month +10.28% +10.28% 3 Month -0.50% -0.50% 6 Month +1.04% +1.04% 1 Year -0.72% -0.72% More News Read More 7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline June 17, 2024 Via InvestorPlace Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants June 13, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session June 13, 2024 Via Benzinga Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants June 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights May 31, 2024 Via Benzinga Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical April 22, 2024 Via Benzinga Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) June 12, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) June 11, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday June 06, 2024 Via Benzinga Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) May 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells May 22, 2024 Via Benzinga Topics Lawsuit Exposures Financial Legal Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 17, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference May 07, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 May 02, 2024 Via InvestorPlace Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update May 02, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease April 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) April 30, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update April 25, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 19, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March April 15, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 15, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
